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Background: Guidelines discourage multi-vessel angioplasty at the time of ST elevation myocardial infarction (STEMI). This was apparently 
confirmed by a recent meta-analysis of predominantly registry data*. However, the results of this analysis may have been exposed to the inherent 
allocation bias within registries; if registry clinicians preferentially allocated STEMI patients with a higher risk of mortality to multi-vessel angioplasty, 
the mortality of this therapy would appear unfairly increased leading to inaccurate conclusions.
Methods: The 10 studies in the Vlaar analysis comparing culprit only to multi-vessel PPCI (35008 patients, 96% of the ‘non-network’ analysis by 
Vlaar et al, 4 registries excluded due to insufficient data) were re-analysed to determine if higher risk patients were more likely to be allocated to 
multi-vessel PPCI. We then performed a weighted random effects meta-regression to determine if biased allocation of high risk patients could explain 
the difference in mortality between the two therapies (STATA Corp, Texas, USA).
Results: We demonstrate that higher risk patients are more likely to be allocated to multi-vessel PPCI (pooled OR 0.80, 95% CI 0.69-0.92); 
furthermore when we adjust for this difference in higher risk patient allocation across the studies there is no mortality difference between culprit 
only and multi-vessel angioplasty at the time of STEMI (adjusted OR 0.86, 95% CI 0.51-1.46).
Conclusions: Our findings highlight the danger of using registry data in meta-analyses comparing competing interventions and suggest multi-
vessel angioplasty at the time of STEMI should not be discouraged on the basis of the current data.
*Vlaar et al. J Am Coll Cardiol. 2011; 58(7):692-703
